http://www.aegis.com/news/ads/2003/AD031357.html

Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.

 

US Company Denies Plan to Abandon AIDS Vaccine Test in Thailand

Associated Press (07.03.03) - Monday, July 07, 2003

On Thursday, VaxGen Inc. denied media reports it would abandon the Thailand trials of its experimental AIDS vaccine. The Bangkok Post and Britain's Guardian reported recently that the company would end its financial support for the trials before a final analysis was done.

Thai medical officials involved in the trial told the Thai press that they had been unofficially informed that VaxGen was pulling out. But in a statement Thursday, VaxGen said it "has every intention of completing its Phase III trial in Thailand, including the final analysis, and announcing the preliminary results, as planned, in the fourth quarter of 2003." The first two phases of the testing began in Bangkok in 1998, and the third phase, involving 2,500 volunteers recruited from drug rehabilitation clinics in the city, was launched in March 1999.

In February, VaxGen announced disappointing results for its AIDSVAX vaccine based on a trial in the United States. It reported there was no meaningful difference in protection between the 3,330 volunteers who received the vaccine and the 1,679 who received a placebo. All the participants were at high risk of contracting HIV.

VaxGen has spent $200 million developing its vaccine, and, despite the US trial results, the company remains hopeful that the vaccine will someday slow the spread of AIDS.
030707
AD031357

Copyright © 2003 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. comments@aegis.org.